September 2024

The FDA jumps to approve when Apple approaches.  This sounded familiar, and merits a look back to a blog post from September 2018: “When Apple speaks, a puzzled market listens. When Apple announces, industries crane their necks to hear. They announced two features of a new watch, ECG monitoring and fall detection. In July, Tim Cook apparently did not want to get into the world of FDA regulation. Well, that was then – or he just wasn’t saying. In this new watch, both the ECG feature and fall detection have received FDA clearance within 30 days of applying, startling some observers who noted that closer to 150 days was more typical for a medical device. Healthcare observers are concerned that false positives from ECG readings could propel people unnecessarily to already-overloaded Emergency Rooms. To date, the Apple Watch may have been of greatest interest to 40 year old males. Interestingly, 70% of cases of atrial fibrillation are among the 65+ population. Does Apple really want the 65+ population to buy an Apple watch?” Did it happen?

Sensor-based remote monitoring of older adults – a good idea in 2009.  That year, GE acquired the sensor-based monitoring technology, QuietCare from Living Independently Group (LIG). Sensors could be placed around the home and alerts transmitted about the older adult – across multiple rooms, motion, and lack of motion could all be detected without a wearable. At that time, the ‘home health monitoring’ market was projected to grow to $7.7 billion by 2012. That did not happen, but fast forward to 2023 – market sizing indicates a sizable ‘remote health monitoring’ space. In the 15 years since the QuietCare acquisition, much has happened – although many players left the space when it was unclear how to make money in it.